BBHC
GLSI icon

Brown Brothers Harriman & Co’s Greenwich LifeSciences GLSI Stock Holding History

Brown Brothers Harriman & Co’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,000
Closed -$44.9K – 1369
2024
Q4 		$44.9K Buy
+4,000
New +$53.5K ﹤0.01% 901

Other funds holding GLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brown Brothers Harriman & Co's GLSI Position: Q1 2025 in Review

Brown Brothers Harriman & Co sold out of Greenwich LifeSciences (GLSI) in Q1 2025, closing a stake of 4,000 shares — an estimated $44.9K sold.

Brown Brothers Harriman & Co first reported a position in GLSI in Q4 2024 and held it in 1 quarter. The position peaked at $44.9K in Q4 2024. 46 funds tracked by Wall St. Rank hold GLSI as of Q1 2025.

  • Brown Brothers Harriman & Co reported no remaining Greenwich LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 4,000 Greenwich LifeSciences shares in Q1 2025, an estimated $44.9K.
  • Brown Brothers Harriman & Co first reported a position in Greenwich LifeSciences in Q4 2024 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Greenwich LifeSciences position peaked at $44.9K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q1 2025.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2025, filed 14 May 2025.